Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies999
Abogen Biosciences
Abogen Biosciences is a biotech company that develops RNA and DNA therapeutics for cancer and infectious diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
Izana Bioscience
Izana Bioscience is a biopharmaceutical company developing innovative science to market.
Sector
Subsector
Location
total rounds
total raised
Hummingbird Bioscience
Hummingbird Bioscience develops antibody-based drugs for oncology patients.
Sector
Subsector
Keywords
Location
total rounds
total raised
Venenum BioDesign
VENENUM Biodesign is a biopharmaceutical company focused on discovering and developing new medicines for various medical needs.
Sector
Subsector
Location
Financials
Funding Rounds8
Number of Funding Rounds
Money Raised
Their latest funding was raised on 19.10.2022. Their latest investor Novartis. Their latest round Series C
Cormorant Asset Management
Cormorant Asset Management is a hedge fund sponsor that focuses on investing in innovative biotechnology and life sciences companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors8
Number of lead investors
Number of investors
Novartis
Novartis is a Swiss healthcare company improving global patient lives.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Cormorant Asset Management
Cormorant Asset Management is a hedge fund sponsor that focuses on investing in innovative biotechnology and life sciences companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Bihua Chen
Bihua Chen is the Founder, CEO & Portfolio Manager at Cormorant Asset Management.
current job
organization founded
V-Bio Ventures
V-Bio Ventures is an independent venture capital firm that finds, builds, and finances young, innovative life science companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Founders2
Nikolai Kley
Prior to joining FORMA, Dr. Kley was Vice President and Head of Research at GPC Biotech. Dr. Kley was an early member of the GPC Biotech management team (1999-2007) and played key roles in developing and advancing the company’s genomics, proteomics, chemical proteomics and biology technology platforms, in attracting and managing multimillion dollar government grants and strategic alliances with pharmaceutical companies, and in building GPC Biotech’s preclinical oncology drug discovery pipeline and translational research capabilities. From 1997-1999 he was Director and Vice President, Functional Genomics, at Genome Therapeutics Corporation. Prior to that Dr. Kley was Senior Research Investigator, Group Leader and Head of Tumor Suppressor Program in the Oncology Division at Bristol Myers Squibb Pharmaceutical Research Institute (Princeton), and a Visiting Research Scholar (Research Professor) at Princeton University. Dr. Kley was a postdoctoral fellow in Neuro-Oncology at Massachusetts General Hospital and Harvard Medical School. He received his Ph.D. in Biochemistry from the Max-Planck Institute (Martinsried, Germany) and Ludwig Maximillian University (Munich, Germany), and was a recipient of the Otto Hahn Medal Award (Max Planck Society) and Junior Investigator Award of the National Neurofibromatosis Foundation, which he later also served as member of the scientific advisory board. He received his B.Sc.Hon. in Biochemistry/Physiology from Leeds University (UK) and his earlier education at the European School in Varese, Italy.
current job
organization founded
Nikolai Kley
Employee Profiles7
Activity
Recent News4
The graph reveals the ratio (%) of positive news articles in a chosen time range